Royalty Rates. Subject to the remainder of this [Section 9.3], Zai shall make quarterly non-refundable, non-creditable royalty payments to NVCR on the Net Sales of all Licensed Products sold in the Territory, calculated by multiplying the applicable royalty rate set forth below by the corresponding amount of incremental, aggregated Net Sales of all Licensed Products sold in the Territory in the applicable Calendar Year. For each Calendar Year, the below tiered royalties are calculated such that the higher tiered royalties are only paid after the annual Net Sales exceed the top threshold of the previous tier.

Royalty Rates. On a Product-by-Product and country-by-country basis, during the Royalty Term, Lilly shall pay to [[Merus:Organization]] a tiered royalty equal to the percentages of annual Net Sales of such Product, as set forth in Table 8.4.2 below (the “Royalty”), calculated by multiplying the applicable royalty rate percentage by the corresponding portion of aggregate Net Sales for such Product in such Calendar Year. Notwithstanding the foregoing, Lilly will only be required to pay [[Merus:Organization]]: ​ of the applicable royalty percentage set forth below for Net Sales of any Reduced Payment Product. For clarity, a Product that incorporates, contains or comprises a Modified Compound is not a Reduced Payment Product, unless such Product otherwise meets the definition of a Reduced Payment Product.

Royalty Rates. In further consideration for the licenses and other rights granted to the Primary Party herein by the Opt-Out Party, subject to the remainder of this Section 9.5(a), the Primary Party shall make quarterly non-refundable, non-creditable royalty payments to the Opt-Out Party on the aggregate Net Sales, on a [[Unknown Identifier]] Opt-Out Product-by-SYNGAP1 Opt-Out Product basis, sold in the Territory in a given Calendar Year, calculated by multiplying the applicable royalty rate set forth below by such Net Sales. The applicable royalty rates set forth in the table below will apply only to that portion of the Net Sales during a given Calendar Year that falls within the indicated range. Net Sales of each [[Unknown Identifier]] Opt-Out Product throughout the Territory will be aggregated for purposes of determining the royalty tiers and royalties, provided that if no royalty is payable on a given unit of [[Unknown Identifier]] Opt-Out Product (i.e., following the expiration of the [[Unknown Identifier]] Royalty Term for such [[Unknown Identifier]] Opt-Out Product in a given country), then the Net Sales of such unit of [[Unknown Identifier]] Opt-Out Product shall not be included in Net Sales for purposes of determining the royalty tiers and royalties due hereunder. All royalty payments, and associated reports, shall be made in accordance with [Section 9.7(c)].

The following royalty rates shall apply to the respective tiers of aggregate Calendar Year Net Sales of a Product in the Roche Royalty Territory, on an incremental basis, as follows:

Royalty Rates. Subject to Section 8.3.3, as further consideration of the obligations imposed on REGENX and rights granted to PARTNER hereunder and under the Penn Sublicense Agreement, commencing upon the First Commercial Sale of a Licensed Product for use in the Licensed Field in any country in the Royalty Territory, PARTNER shall pay to REGENX a royalty on Net Sales of each Licensed Product for use in the Licensed Field in the Royalty Territory during ​ in the Royalty Term for each such Licensed Product in the applicable country in the Royalty Territory, at the following rates:

Royalty Rates. Subject to the remainder of this Section 8.7, in addition to the payments set forth in Section 8.7(a), Sana shall pay Beam ​ of all Net Sales of each Licensed Product sold by Sana, its Affiliates or Sublicensees during the Royalty Term.

Royalty Rates. Licensee shall pay [[AstraZeneca:Organization]] a royalty based on Net Sales of each Licensed Product in the Field in the Territory during each Calendar Year during the Royalty Term at the following rates set forth below in this Section 4.4.1 (as adjusted by the other terms of this Section 4.4, each, a “Royalty”), in accordance with [Section 4.5].

Royalty Rates. On a Licensed Product-by-Licensed Product and country-by-country basis, [[FibroGen:Organization]] will pay HFB royalties on aggregate annual Net Sales of each Licensed Product in the Territory in a Calendar Year at the royalty rates set forth in Table 8.4(a) until the expiration of the Royalty Term for such Licensed Product on a country-by-country basis (“Royalties”).

Royalty Rates. In further consideration for the licenses and other rights granted to Acadia herein by Stoke, subject to the remainder of this Section 9.2(c), Acadia shall make quarterly non-refundable, non-creditable royalty payments to Stoke on the aggregate Net Sales, on a [[Unknown Identifier]] Licensed Product-by- [[Unknown Identifier]] Licensed Product basis, sold in the Territory in a given Calendar Year, calculated by multiplying the applicable royalty rate set forth below by such Net Sales. The applicable royalty rates set forth in the table below will apply only to that portion of the Net Sales during a given Calendar Year that falls within the indicated range. Net Sales of each [[Unknown Identifier]] Licensed Product throughout the Territory will be aggregated for purposes of determining the royalty tiers and royalties, provided that if no royalty is payable on a given unit of [[Unknown Identifier]] Licensed Product (i.e., following the expiration of the [[Unknown Identifier]] Royalty Term for such [[Unknown Identifier]] Licensed Product in a given country), then the Net Sales of such unit of [[Unknown Identifier]] Licensed Product shall not be included in Net Sales for purposes of determining the royalty tiers and royalties due hereunder. All royalty payments, and associated reports, shall be made in accordance with [Section 9.7(c)].

Royalty Rates. In further consideration for the licenses and other rights granted to Acadia herein by Stoke, subject to the remainder of this [Section 9.3(c)], Acadia shall make quarterly non-refundable, non-creditable royalty payments to Stoke on the aggregate Net Sales, on a ​ Licensed Product-by-​ Licensed Product basis, sold in the Territory in a given Calendar Year, calculated by multiplying the applicable royalty rate set forth below by such Net Sales. The applicable royalty rates set forth in the table below will apply only to that portion of the Net Sales during a given Calendar Year that falls within the indicated range. Net Sales of each ​ Licensed Product throughout the Territory will be aggregated for purposes of determining the royalty tiers and royalties, provided that if no royalty is payable on a given unit of ​ Licensed Product (i.e., following the expiration of the ​ Royalty Term for such ​ Licensed Product in a given country), then the Net Sales of such unit of ​ Licensed Product shall not be included in Net Sales for purposes of determining the royalty tiers and royalties due hereunder. All royalty payments, and associated reports, shall be made in accordance with [Section 9.7(c)].